Navigation Links
BioVex to Present at the UBS Global Life Sciences Conference
Date:9/18/2008

WOBURN, Mass., Sept. 18 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced that Philip Astley-Sparke, President and CEO, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 25th at 8:00 A.M. The conference is being held at the Grand Hyatt New York in New York, NY.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEXGM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEXGM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.

BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Earlier this year, the Company announced that the FDA approved the design of a single, pivotal Phase III clinical trial evaluating OncoVEXGM-CSF in previously treated patients with metastatic melanoma under the Special Protocol Assessment (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. BioVex intends to begin its Phase III trial for OncoVEXGM-CSF in melanoma in the first quarter of 2009.

BioVex recently announced that the
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
3. BioVex Closes Second Round of Series E Financing
4. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
5. Avicena Group to Present at Noble Financial Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CEL-SCI to Present at the Noble Financial Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... On Thursday, September 11, 2014, the NASDAQ Composite ... finished the day 0.12% lower at 17,049.00, and the S&P ... based as seven out of ten sectors ended the session ... the day at 741.83, down 0.33%, while the index has ... coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
(Date:9/11/2014)... one atom thick sheet of carbon, can be randomly ... of graphene that could have a significant impact on ... it could provide an ultra-strong, non-corrosive coating for a ... solutions can be used to paint various surfaces ranging ... a simple chemical treatment, the resulting coatings behave like ...
Breaking Biology Technology:Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... (OTCBB:IAGX) announced today it has appointed Bill Toomey to ... the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer ... join our board and bring to us his extensive ... benefit greatly from his past experiences and high level ...
... BELL, Pa., June 30, 2011 Inovio Pharmaceuticals, Inc. ... the development of therapeutic and preventive vaccines against cancers ... compelling immune responses in a study of its multi-subtype ... proprietary vaccine delivery technology in sheep, the second large ...
... ORLEANS, June 29, 2011 Ochsner Health System has signed ... e ICU Program to enhance critical care -- a program ... of stay and save lives. As the only healthcare provider ... Ochsner will serve as a statewide resource to community and ...
Cached Biology Technology:Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 3Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 4Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 5Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 6Ochsner Health System will Offer First eICU Program in Louisiana 2Ochsner Health System will Offer First eICU Program in Louisiana 3
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... is no published account where hippopotamuses are demonstrably shown ... of water. But if they can,t swim, how did ... widely accepted models for the methods, patterns, and timing ... Cyprus, Crete, and Madagascar) may need to be reconsidered. ... the mainland are not currently supported by positive ...
(Date:9/15/2014)... the proteins in our cells cooperate with one another. ... of thousands of different proteins find the correct dancing ... body, brain and nervous system. A recent breakthrough at ... down the door and provided a look at the ... Professor emeritus Jens Jrgen Led of the University of ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Protein courtship revealed through chemist's lens 2Protein courtship revealed through chemist's lens 3
... at the second European Lung Cancer Conference shows ... small-cell lung cancer benefit in terms of overall ... Patients treated with hyperfractionated or accelerated radiotherapy ... over a shorter period of time. The benefit ...
... radiotherapy using real-time X-ray images has allowed French doctors to ... liver cancers while minimizing harm to nearby healthy tissue, researchers ... this study we show that it is possible and very ... at any time before or during treatment in terms of ...
... In this latest image acquired by ESA,s Envisat on Thursday ... Gulf of Mexico can be seen as a dark blue ... the oil spill five times larger than first estimated ... coast, threatening environmental disaster. , As efforts are being made ...
Cached Biology News:Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer 2Oil spill in the Gulf of Mexico nears the coast 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Biology Products: